Russell Johnson
Independent Expert Moderna
Russell Johnson has spent 15 years in the biotechnology industry, specializing in non-viral delivery systems for mRNA and other oligonucleotide and nucleic acid technologies. He currently leads discovery efforts as Head of Delivery Sciences within the R&D organization at Moderna Therapeutics. Previously, he held roles of increasing responsibility across both large pharmaceutical and small biotechnology organizations. Russell brings deep expertise in lipid, polymeric, and inorganic nanoparticle platforms for mRNA delivery and is the author or inventor on more than 40 peer-reviewed publications and patents.
Seminars
Thursday 4th June 2026
Roundtable Discussion: Discussing Targeted LNP Design to Minimize Immunogenicity, Maximize Safety, & Protect Sensitive Tissues for Extrahepatic Applications
2:00 pm
- How can lipid chemistry and functional group modifications be leveraged to reduce toxicity and off-target effects while maintaining delivery efficiency?
- Which design strategies and targeting ligand modifications best balance tissue specificity, immunogenicity, and safety across sensitive extrahepatic targets?
- How can LNP formulations be engineered to mitigate immune recognition and anti-drug antibody formation to achieve tolerable repeat dosing?
Wednesday 3rd June 2026
Panel Discussion: Exploring the Future of Extrahepatic LNPs to Overcome Delivery Barriers, Expand Therapeutic Reach, & Unlock Novel Disease Treatments
2:40 pm
- What are the remaining barriers for achieving efficient, organ-specific delivery to difficult targets?
- Which design strategies and technologies are most promising for enabling precise extrahepatic targeting while minimizing liver accumulation?
- What unmet therapeutic needs could next-generation extrahepatic LNPs address to expand the RNA, gene editing, and cell therapy landscape?
